Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003126 · ClinicalTrials.gov registry record · Phase 3
Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer
A Phase 3 study, sponsored by Loyola University.
- Completed
- Registry status
- Phase 3
- Development phase
- 69
- Enrollment target
NCT00003126 is a Phase 3 study that has completed, run by Loyola University. The registered enrollment target is 69 participants.
The verdict
NCT00003126, a Phase 3 study, has completed, sponsored by Loyola University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 69 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy of post-operative high-dose bolus interleukin-2 (IL-2) in patients with high-risk renal cell carcinoma (RCC).
Interventions
- DRUG Interleukin-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 1997-06 |
| Est. Completion | 2002-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003126
The ClinicalTrials.gov registry entry for NCT00003126 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loyola University, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interleukin-2 is the first listed.
NCT00003126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003126 about?
NCT00003126 is a clinical study titled "Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer". The purpose of this study is to assess the efficacy of post-operative high-dose bolus interleukin-2 (IL-2) in patients with high-risk renal cell carcinoma (RCC).
What is the current status of trial NCT00003126?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 69 participants. The study started on 1997-06. Estimated completion is 2002-08.
What interventions are being tested in trial NCT00003126?
The interventions under investigation include: Interleukin-2 (DRUG).
Who is sponsoring clinical trial NCT00003126?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.